Erythromycin Lactobionate for Injection

This product belongs to the macrolide antibiotics, which is a water-soluble erythromycin lactobionate. It has antibacterial activity against Staphylococcus, various groups of streptococci and Gram-positive bacilli. Neisseria, Haemophilus influenzae, Bordetella pertussis, etc. may also be sensitive to this product. This product also has antibacterial activity against various anaerobic bacteria except Bacteroides fragilis and Fusobacterium; it also has inhibitory effects on Legionella, Campylobacter fetus, some spirochetes, Mycoplasma pneumoniae, Rickettsia and Chlamydia. This product is an antibacterial agent, but it also has a bactericidal effect on some Newbacteria at high concentrations. This product can pass through the bacterial cell membrane and reversibly bind to the 50S subunit of the bacterial ribosome near the donor site (P site), blocking the transfer RNA (l-RNA) binding to the P site, and also blocking the displacement of the polypeptide chain from the acceptor site (A site) to the P site, thereby inhibiting bacterial protein synthesis. Erythromycin is only effective against bacteria that actively divide.

Erythromycin lactobionate

This product can be used as an alternative to penicillin allergy for the following infections: 1. Acute tonsillitis, acute pharyngitis, sinusitis caused by hemolytic streptococci, pneumococcus, etc.; scarlet fever and cellulitis caused by hemolytic streptococci; diphtheria and diphtheria carriers; gas gangrene, anthrax, tetanus; actinomycosis; syphilis; listeriosis, etc. 2. Legionnaires' disease. 3. Mycoplasma pneumonia. 4. Chlamydia pneumoniae pneumonia. 5. Urinary and reproductive system infections caused by Chlamydia and Mycoplasma. 6. Chlamydia trachomatis conjunctivitis. 7. Neisseria gonorrhoeae infection. 8. Oral infection caused by anaerobic bacteria. 9. Campylobacter jejuni enteritis. 10. Whooping cough.

Intravenous drip: 0.5-1.0g (2-4 bottles) for adults, 2-3 times a day. The dose for treating Legionnaires' disease can be increased to 3-4g (16 bottles) a day. Children should take 20-30mg/kg per day, divided into 2-3 times. To prepare erythromycin lactobionate infusion, first add 10ml of sterile injection water to a 0.5g erythromycin lactobionate powder injection bottle or add 20ml to a 1g erythromycin lactobionate powder injection bottle, and shake vigorously until dissolved. Then dilute it with physiological saline or other electrolyte solutions, and slowly drip it intravenously. Note that the erythromycin concentration should be within 1%-5%. After dissolution, it can also be diluted with a solution containing glucose, but because the glucose solution is acidic, 1ml of 4% sodium bicarbonate must be added to every 100ml of solution.

1 Gastrointestinal reactions are common, including abdominal pain, nausea, vomiting, upper and middle abdominal pain, pain in the mouth and tongue, decreased appetite, etc., and the incidence is related to the dose. 2 Hepatotoxicity is rare, and patients may experience fatigue, nausea, vomiting, abdominal pain, fever, abnormal liver function, and occasional jaundice. 3 When used in large doses (ge; 4g/day), especially in patients with liver and kidney diseases, hearing loss may occur, which is mainly related to excessive blood drug concentration (12mg/L). Most patients can recover after drug withdrawal. 4 Allergic reactions are manifested as drug fever, rash, eosinophilia, etc., with an incidence of about 0.5%-1%. 5 Occasionally, there are arrhythmias and oral or cavity Candida infections.

It is contraindicated for patients who are allergic to erythromycin.

1. This product can inhibit the metabolism of antiepileptic drugs such as carbamazepine and valproic acid, resulting in an increase in the latter's blood concentration and toxic reactions. This product can inhibit the latter's metabolism and prolong its duration of action when used in combination with alfentanil. This product can increase cardiac toxicity when used in combination with antihistamines such as astemizole or terfenadine, and can increase the latter's blood concentration and produce nephrotoxicity when used in combination with cyclosporine. 2. This product has an antagonistic effect with chloramphenicol and lincosamides, and is not recommended for combined use. 3. This product is an antibacterial agent that can interfere with the bactericidal efficacy of penicillin. Therefore, when a rapid antiviral effect is required, such as the treatment of meningitis, the two should not be used together. 4. Patients who have been taking warfarin for a long time may experience a prolonged prothrombin time when using erythromycin, thereby increasing the risk of bleeding. Elderly patients should pay special attention. When the two must be used together, the dose of warfarin should be appropriately adjusted and the prothrombin time should be closely observed. 5. Except for dihydroxypropylphylline, the combination of this product with xanthines can reduce the hepatic clearance of aminophylline, leading to increased serum aminophylline concentrations and (or) increased toxic reactions. This phenomenon is more likely to occur after 6 days of co-use, and the reduction in aminophylline clearance is proportional to the serum peak value of this product. Therefore, the dose of xanthines should be adjusted during and after the combined treatment of the two. 6. Combination with other hepatotoxic drugs may enhance hepatotoxicity. 7. The combination of large doses of this product with ototoxic drugs, especially in patients with renal impairment, may increase ototoxicity. 8. When used in combination with lovastatin, its metabolism can be inhibited and blood concentrations can be increased, which may cause rhabdomyolysis. When used in combination with midazolam or triazolam, the clearance of the two can be reduced and their effects can be enhanced.

Keep in a sealed, dry place. Valid for three years.

0.25g (250,000 units)

Fuan Pharmaceutical Group Hubei Renmin Pharmaceutical Co., Ltd.

• Founded in:

  2001-11-13

• Address:

  No. 1 Qijiashante, Baiquan, Dongxihu District, Wuhan

• Tax NO.:

  91420112732707909X

• Registered Funds:

  111.99 million yuan

• Website:

  Log in to view

• Email:

  Log in to view